Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
19.97 ^USD	-2.96%		-9.64%	-28.81%

May. 09	Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating	MT
May. 08	Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

May 08, 2024 at 04:10 pm EDT

Pharvaris N.V. announced that Schmidt, J.D., Chief Legal Officer of Pharvaris, has given notice of her resignation, effective June 1, 2024. David Nassif, J.D., Chief Financial Officer of Pharvaris, will assume oversight of the legal and compliance department and will act as the corporate secretary until a successor joins the company.

Latest news about Pharvaris N.V.

Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating	May. 09	MT
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024	May. 08	CI
Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	Apr. 15	MT
Pharvaris Files Mixed Shelf	Apr. 12	MT
Pharvaris Narrows Q4 Net Loss; Hires New CFO	Apr. 10	MT
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	Apr. 10	CI
JMP Securities Raises Pharvaris' Price Target to $49 From $40, Maintains Market Outperform Rating	Jan. 23	MT
Pharvaris Says FDA Lifts Clinical Hold on Application for Potential Treatment of Hereditary Angioedema Attacks	Jan. 22	MT
Correction: Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 22	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 22	MT
Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant	Jan. 22	DJ
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks	Jan. 22	CI
Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023	Dec. 08	CI
Morgan Stanley Raises Price Target on Pharvaris to $35 From $32, Keeps Overweight Rating	Dec. 07	MT
Wedbush Raises Pharvaris' Price Target to $35 From $24, Outperform Rating Kept	Dec. 06	MT
Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...	Dec. 06
Job losses delight investors	Dec. 06
Sector Update: Health Care Stocks Mixed Premarket Wednesday	Dec. 06	MT
Sector Update: Health Care	Dec. 06	MT
Pharvaris' Phase 2 Study of Deucrictibant Meets Primary Endpoint; Prices $300 Million Offering; Shares Jump 42% Pre-Bell	Dec. 06	MT
Top Premarket Gainers	Dec. 06	MT
Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks	Dec. 06	CI
Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer	Nov. 15	CI

Chart Pharvaris N.V.

Duration

Period

More charts

Company Profile

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - Eastern Allergy Conference - Henry Li

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.43 EUR

Average target price

30.87 EUR

Spread / Average Target

+67.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARVARIS N.V.	-28.81%	1.07B
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+45.55%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B

Other Biotechnology & Medical Research